The US Food and Drug Administration has approved a new non-opioid treatment for pain that targets a signalling pathway in the peripheral nervous system before pain signals reach the brain. The drug, Journavx (suzetrigine), is the first drug in a new class of medicines for the treatment of moderate to severe acute pain arising from trauma or surgery. Typically, these cases may be treated with prescription opioids.
